Registry of Sarcoidosis Associated Pulmonary Hypertension (RESAPH)

University of Cincinnati300 enrolled

Overview

Registry to follow patients with sarcoidosis associated pulmonary hypertension

This is a multi center registry of sarcoidosis associated pulmonary hypertension (SAPH). With this registry, the investigators will characterize the demographics, clinical course, hemodynamics, pulmonary physiology, and disease management of sarcoidosis associated pulmonary hypertension on the United States. The investigators will also compare these features to non-US sites.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Sarcoidosis Pulmonary Hypertension

Interventions

ObservationOTHER

Observe patients

Eligibility

Sex: ALLMin age: 18 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with sarcoidosis as defined by the ATS/WASOG statement * Patients with pulmonary hypertension as confirmed by right heart catheterization * Patients willing to provide written informed consent Exclusion Criteria: * Unwillingness to provide assurance that they will complete the follow up visits for the study

Locations (1)

University of Cincinnati

Cincinnati, Ohio, United States

RECRUITING

Outcomes

Primary Outcomes

Survival

Mortality during time of study

Time frame: 4 years

Secondary Outcomes

Disease management

Examine initial and follow up management

Time frame: 4 years

Central Contacts

Robert P Baughman, MD

CONTACT

513-584-5225 bob.baughman@uc.edu

Rebecca Ingledue

CONTACT

513-584-6252

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.